A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (HGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration With PK-triggered Expansion Cohort
This study tests an experimental drug called BDTX-1535 for people with certain types of aggressive brain tumors. Researchers want to see if the drug can safely reach the brain and block a specific growth signal that helps these tumors grow.
You may be able to join if you have a fast-growing brain tumor that has returned or is newly diagnosed, and your tumor tissue has specific changes in the EGFR gene. Participants must also be scheduled for surgery to remove part of their tumor and meet overall health requirements.
Participants will take the experimental study drug before their scheduled tumor removal surgery to see how well it enters the brain tissue. Depending on your specific group, you may also receive standard treatments like radiation therapy and chemotherapy after surgery.
This study is currently active and recruiting participants in locations including Chandler and Phoenix, Arizona. Your study doctor can provide exact clinic details and help you understand the schedule.
- 1Tests a new targeted drug called BDTX-1535 for certain brain tumors
- 2Requires specific genetic changes in the tumor known as EGFR alterations
- 3Involves taking the study drug before a scheduled brain surgery
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.